EUVIMEDEUVIMED entdecken
Crossref

Roxadustat Versus ESA Therapy for Sustained Hemoglobin Response in ESA ‐Hyporesponsive Hemodialysis Patients

Mehmet Demir iD, Ilyas Ozturk iD, Merve Aktar iD, Cihan Heybeli iD, Can Huzmeli iD, Orhan Ozdemir iD, Seda Safak Ozturk iD, Tulin Akagun iD, Neriman Sila Koc iD, Mehmet Tuncay iD, Ekrem Kara iD, Tuncay Sahutoglu iD

Hemodialysis International · 14.07.2026

DOI: 10.1111/hdi.70116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemodialysis International, online erschienen am 14.07.2026. Verfasst von Mehmet Demir und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Health Sciences-Mehmet Akif Inan Education and Research Hospital, Sanliurfa, Türkiye. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Erythropoiesis‐Stimulating Agent (ESA)‐hyporesponsive hemodialysis patients, hemoglobin (Hb) change from baseline may not fully capture durable treatment response. This secondary analysis evaluated sustained Hb ≥ 10 g/dL achievement and month‐to‐month Hb variability with roxadustat versus continued ESA therapy.

Methods

This multicenter retrospective secondary analysis included adult maintenance hemodialysis patients with ESA‐hyporesponsive anemia and complete monthly Hb data from Months 1–6. Sustained target achievement was defined as Hb ≥ 10 g/dL in at least 3 of 6 months. Hb variability was assessed using within‐patient Hb SD, coefficient of variation, range, mean absolute monthly change, and maximum absolute change. Predictors were evaluated using logistic and linear regression.

Results

Among 108 patients, 78 received roxadustat and 30 continued ESA therapy. Sustained Hb ≥ 10 g/dL achievement occurred in 52 patients. Roxadustat was associated with higher adjusted odds of sustained target achievement versus ESA therapy (adjusted OR: 4.44, 95% CI: 1.24–15.84; p = 0.022). Higher baseline Hb was also independently associated with sustained response (adjusted OR: 2.95 per 1 g/dL, 95% CI: 1.57–5.55; p < 0.001). By Month 6, Hb ≥ 10 g/dL was achieved by 50.0% of roxadustat‐treated patients versus 33.3% of ESA‐treated patients. Hb variability metrics were numerically lower with roxadustat but were not significantly different between groups.

Conclusions

In ESA‐hyporesponsive hemodialysis patients, roxadustat was associated with higher adjusted odds of sustained Hb ≥ 10 g/dL achievement but did not clearly reduce month‐to‐month Hb variability over 6 months. These retrospective findings support sustained target achievement as a clinically relevant response metric and warrant prospective validation.

Schlagwörter

Stichwörter der Autor:innen

anemiaerythropoiesis‐stimulating agenthemoglobinroxadustat

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Health Sciences-Mehmet Akif Inan Education and Research Hospital, Sanliurfa, Türkiye.
  • Department of Nephrology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Türkiye.
  • Department of Nephrology, Istanbul Aydin University, Medical Park Florya Hospital, Istanbul, Türkiye.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Türkiye.
  • Department of Nephrology, Hatay Education and Research Hospital, Hatay, Türkiye.
  • Department of Nephrology, Gaziantep Sanko University Hospital, Gaziantep, Türkiye.

ORCID-Profile: Mehmet Demir, Ilyas Ozturk, Merve Aktar, Cihan Heybeli, Can Huzmeli, Orhan Ozdemir, Seda Safak Ozturk, Tulin Akagun, Neriman Sila Koc, Mehmet Tuncay, Ekrem Kara, Tuncay Sahutoglu

Zitieren

APA

Demir, M., Ozturk, I., Aktar, M., Heybeli, C., Huzmeli, C., Ozdemir, O., Ozturk, S. S., Akagun, T., Koc, N. S., Tuncay, M., Kara, E., & Sahutoglu, T. (2026). Roxadustat Versus ESA Therapy for Sustained Hemoglobin Response in ESA ‐Hyporesponsive Hemodialysis Patients. Hemodialysis International. https://doi.org/10.1111/hdi.70116

Vancouver

Demir M, Ozturk I, Aktar M, Heybeli C, Huzmeli C, Ozdemir O, et al. Roxadustat Versus ESA Therapy for Sustained Hemoglobin Response in ESA ‐Hyporesponsive Hemodialysis Patients. Hemodialysis International. 2026. doi:10.1111/hdi.70116

BibTeX
@article{Demir2026,
  author = {Demir, Mehmet and Ozturk, Ilyas and Aktar, Merve and Heybeli, Cihan and Huzmeli, Can and Ozdemir, Orhan and Ozturk, Seda Safak and Akagun, Tulin and Koc, Neriman Sila and Tuncay, Mehmet and Kara, Ekrem and Sahutoglu, Tuncay},
  title = {Roxadustat Versus ESA Therapy for Sustained Hemoglobin Response in ESA ‐Hyporesponsive Hemodialysis Patients},
  journal = {Hemodialysis International},
  year = {2026},
  doi = {10.1111/hdi.70116}
}
Kostenlos starten →